Record overview
Status and phase
Status: COMPLETED
Phase: PHASE1, PHASE2
Sponsor: National Cancer Institute (NCI)
Condition: Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Refractory Childhood Hodgkin Lymphoma
NCT01780662
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.